Navigation Links
Industry Leaders Select Resverlogix's RVX-208
Date:7/9/2008

Among top 10 most promising drugs

TSX Exchange Symbol: RVX

CALGARY, July 9 /PRNewswire-FirstCall/ - Resverlogix Corp's ("Resverlogix" or the "Company") (TSX:RVX) novel lead ApoA-I drug candidate, RVX-208 has been selected as one of the top 10 most promising cardiovascular disease (CVD) drugs available for strategic partnering by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.

"We are honored to be part of this select group of top ten most promising innovative drugs," stated Donald McCaffrey, President and CEO of Resverlogix. "It again validates RVX-208 and our entire NexVas(TM) PR franchise as an important new small molecule drug for the largest market with unmet needs, atherosclerosis and cardiovascular diseases. We are moving towards our next important milestone, Phase 1b/2a, later this fall and continue to measure safety, tolerability and key reverse cholesterol transport (RCT) markers such as ApoA-I, pre-beta HDL, HDL and cholesterol efflux."

The selection committee was led by Marc Wortman, PhD, contributing writer to Windhover's IN VIVO and Start Up publications, and Michael Rice, Senior Consultant, and Ed Saltzman, President of Defined Health, a leading business development strategy consulting firm. Drawing on the analytic resources of these organizations, the group evaluated hundreds of compounds currently in development for the treatment of cardiovascular disease prior to selecting RVX-208 among the top ten most attractive drug available for partnering.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award, and represent what our committee considered the most attractive cardiovascular opportunities the industry has to offer," stated Roger Longman, Managing Director of Wi
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
5. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
6. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
7. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
8. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
9. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
10. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
11. Suntech to Attend Upcoming Investor Conferences and Industry Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013 PuraMed BioScience ® , ... of over-the-counter (OTC) medicinal and healthcare products, announced ... the company based on low market capitalization valuation. ... All Natural Product to Treat Migraine Headaches ... Prescription Competitor , Currently Available Nationwide at ...
(Date:5/23/2013)... PI’s new LPS-24 positioners are ... mm travel range with closed-loop sensor resolution up ... these new positioners the ideal choice for high ... version is also available. , More Information: ... be found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 , ...
(Date:5/23/2013)... PARK, Calif. , May 23, 2013 ... oral treatment for pain has reached an important milestone, ... trial of VBY-036 - a selective cathepsin S inhibitor. ... VBY-036 is a double-blind, randomized, placebo-controlled study designed to ... doses of VBY-036 in healthy adults. "The ...
(Date:5/23/2013)... , May 23, 2013 Z Trim ... value-added ingredients to a variety of industries, announced that ... a panel discussion at this year,s National Restaurant Association ... 2013, on behalf of the Research Chefs Association.  Chef ... Restaurants: The Good, the Bad and the Ugly," joining ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3
... of ... Directors, ... its platform technology to identify and,develop compounds that promote the growth ... announced today that it has,completed a $30 million initial closing of ...
... N.J., March 10 Palatin,Technologies, Inc. (Amex: ... Phase I,clinical trial of PL-3994, a novel, long-acting ... treatment of acute,decompensated congestive heart failure (CHF). The ... single ascending dose study,in 26 healthy volunteers who ...
... leader in,developing automated molecular testing solutions, announced today ... biotechnology companies presenting,at the 28th Annual Cowen Health ... Marriott Copley Place in Boston, Massachusetts. Fareed Kureshy,President ... of the,company, its automated molecular testing platform and ...
Cached Biology Technology:BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 2Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 3Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure 4
(Date:5/24/2013)... Orleans, LA After studying noise in one French ... not noise levels exceeded municipal ordinances, Annette Hurley, PhD, ... New Orleans, and Eric Arriaga, a third-year LSUHSC doctor ... to protect their own hearing health. Their case study ... Advance for Hearing Practice Management ., "An important part ...
(Date:5/23/2013)... , Automated conserved noncoding sequence ... evolution among grasses , Within the genome of ... that undergo little change in position and sequence over ... proteins. Some of these evolutionarily stable sequences, so-called conserved ... of other genes or the condensation of chromosomes, but ...
(Date:5/23/2013)... More than 13,000 ships per year, carrying more than 284 ... generating roughly $1.8 billion dollars in toll fees for the ... than 55 million gallons of water are used from Gatun ... 2 million people living in the isthmus. , However, ... than 20 percent of the ships at sea, has demanded ...
Breaking Biology News(10 mins):Please do try this at home 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... Society for Microbiology (ASM) BD Award for Research ... Stephen Dumler, M.D., Professor, The Johns Hopkins University ... Diagnostic Systems, this award recognizes a distinguished scientist ... important applications in clinical microbiology. Dumler,s most ...
... release is available in German . ... epoch, around 115,000 years ago, there were significant climate ... from the Eemian Interglacial to the Weichselian Glacial was ... possibly at least two warming events. This is the ...
... caused more than $193 million in hospital-based medical care ... problems such as asthma and pneumonia that are triggered ... Corporation study. Researchers estimate that exposure to excessive ... emergency room visits and hospital admissions over the study ...
Cached Biology News:American Society for Microbiology honors J. Stephen Dumler 2Were short warm periods typical for transitions between interglacial and glacial epochs? 2Study finds dirty air in California causes millions worth of medical care each year 2Study finds dirty air in California causes millions worth of medical care each year 3
TNR-R2...
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
Biology Products: